Vanguard Capital Management
IMVT icon

Vanguard Capital Management’s Immunovant IMVT Stock Holding History

Vanguard Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140M Buy
3,638,681
+18,631
+0.5% +$568K ﹤0.01% 1358
2026
Q1 		$89.9M Buy
+3,620,050
New +$93.7M ﹤0.01% 1528

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Capital Management's IMVT Position: Q2 2026 in Review

Vanguard Capital Management increased its Immunovant (IMVT) stake by 0.51% in Q2 2026, buying an estimated $568K and bringing the position to 3,638,681 shares worth $140M. The position accounts for ﹤0.01% of the portfolio, ranked #1358.

Vanguard Capital Management first reported a position in IMVT in Q1 2026 and has held it in 2 quarters since. 225 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Vanguard Capital Management held 3,638,681 shares of Immunovant worth $140M as of Q2 2026.
  • Vanguard Capital Management bought 18,631 Immunovant shares in Q2 2026, an estimated $568K.
  • Immunovant made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1358 holding.
  • Vanguard Capital Management first reported a position in Immunovant in Q1 2026 and has held it in 2 quarters since.
  • 225 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.